Research Article
MicroRNA-1224-5p Aggravates Sepsis-Related Acute Lung Injury in Mice

Bing Liu,1 Feng Chen,2 Ni-Tao Cheng,3 Zheng Tang,3 Xian-Guo Wang,3 and Ming Xu1,3

1Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei, China
2Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei, China
3Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei, China

Correspondence should be addressed to Ming Xu; xumingznhospital@163.com

Received 9 August 2021; Accepted 6 June 2022; Published 28 June 2022

Academic Editor: Lixin Xie

Copyright © 2022 Bing Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oxidative stress and inflammation are implicated in the development of sepsis-related acute lung injury (ALI). MicroRNA-1224-5p (miR-1224-5p) plays critical roles in regulating inflammatory response and reactive oxygen species (ROS) production. The present study is aimed at investigating the role and underlying mechanisms of miR-1224-5p in sepsis-related ALI. Mice were intratracheally injected with lipopolysaccharide (LPS, 5 mg/kg) for 12 h to induce sepsis-related ALI. To manipulate miR-1224-5p level, mice were intravenously injected with the agomir, antagomir, or matched controls for 3 consecutive days. Murine peritoneal macrophages were stimulated with LPS (100 ng/mL) for 6 h to further validate the role of miR-1224-5p in vitro.

To inhibit adenosine 5′-monophosphate-activated protein kinase alpha (AMPKα) or peroxisome proliferator activated receptor-gamma (PPAR-γ), compound C or GW9662 was used in vivo and in vitro. We found that miR-1224-5p levels in lungs were elevated by LPS injection, and that the miR-1224-5p antagomir significantly alleviated LPS-induced inflammation, oxidative stress, and ALI in mice. Conversely, the miR-1224-5p agomir aggravated inflammatory response, ROS generation, and pulmonary dysfunction in LPS-treated mice. In addition, the miR-1224-5p antagomir reduced, while the miR-1224-5p agomir aggravated LPS-induced inflammation and oxidative stress in murine peritoneal macrophages. Further findings revealed that miR-1224-5p is directly bound to the 3′-untranslated regions of PPAR-γ and subsequently suppressed PPAR-γ/AMPKα axis, thereby aggravating LPS-induced ALI in vivo and in vitro. We demonstrate for the first time that endogenous miR-1224-5p is a critical pathogenic factor for inflammation and oxidative damage during LPS-induced ALI through inactivating PPAR-γ/AMPKα axis. Targeting miR-1224-5p may help to develop novel approaches to treat sepsis-related ALI.

1. Introduction

Acute lung injury (ALI) and its severe form, adult respiratory distress syndrome (ARDS), are life-threatening conditions and cause great mortality to clinical patients, especially those in the intensive care unit [1–3]. Sepsis functions as a common cause of ALI and ARDS, and sepsis-related ALI is characterized as unrestrained inflammatory response and excessive reactive oxygen species (ROS) production in lungs [4, 5]. Till now, no effective and specific approaches are available to treat ALI. Adenosine 5′-monophosphate-activated protein kinase alpha (AMPKα) is a multifunctional protein kinase and plays critical roles in controlling inflammation and oxidative stress except for energy homeostasis [6–8]. Emerging studies have also identified an indispensable role of AMPKα in the pathogenesis of sepsis-related ALI. Accordingly, Jiang et al. recently revealed that AMPKα activation significantly suppressed intrapulmonary inflammation and ROS generation, thereby preventing lipopolysaccharide- (LPS-) induced ALI in mice [4]. Peroxisome proliferator activated receptor-gamma (PPAR-γ) is known to act not only on glycolipid metabolism but also on inflammation and oxidative stress in various lung diseases [9–11]. Zhang et al. reported that PPAR-γ activation could suppress the activity of nuclear factor-kappa B (NF-κB) and subsequently reduced LPS-induced pulmonary inflammation and ALI [12]. In addition, PPAR-γ activation also prevented inflammation and oxidative damage in
chronic obstructive pulmonary disease [13]. More importantly, PPAR-γ knockdown dramatically augmented hyperoxia-induced inflammation, oxidative stress, and ALI in mice [14]. Taken together, these findings define AMPKα and PPAR-γ as promising therapeutic candidates to treat sepsis-related ALI.

MicroRNAs (miRNAs) are endogenous, single-stranded noncoding RNAs, and are implicated in multiple cellular processes through binding to the 3′-untranslated regions (UTR) of target messenger RNAs (miRNAs) for translational repression or degradation [15–18]. It is estimated that more than 2000 miRNAs are encoded by the human genome, and they regulate about 60% of all mammalian genes. Dysregulated miRNAs have been detected and validated to participate in the progression of sepsis-related ALI. Our recent study showed that miR-762 expression was increased in LPS-treated lungs, and that the miR-762 antagomir significantly alleviated miR-762-untranslated regions (UTR) of target messenger RNAs (mRNAs) for translational repression or degradation [15–18]. It is estimated that more than 2000 miRNAs are encoded by the human genome, and they regulate about 60% of all mammalian genes. Dysregulated miRNAs have been detected and validated to participate in the progression of sepsis-related ALI. Our recent study showed that miR-762 expression was increased in LPS-treated lungs, and that the miR-762 antagomir significantly alleviated miR-762-expressing in the spleen, kidney, and lung, and that its level was elevated by LPS stimulation [23]. And findings from Cheng et al. revealed that miR-1224-5p was also elevated in L02 hepatocytes by hydrogen peroxide stimulation, and that downregulation of miR-1224-5p significantly alleviated hydrogen peroxide-stimulated apoptosis of hepatocytes [24]. Moreover, Li et al. demonstrated that inhibition of miR-1224-5p dramatically suppressed hypoxia/reoxygenation-induced oxidative stress and apoptosis in H9C2 cardiomyocytes [25]. Based on these data, we herein aim to investigate the role of miR-1224-5p in sepsis-related ALI and also try to validate the involvement of AMPKα and PPAR-γ in this process.

2. Material and Methods

2.1. Reagents. LPS from *Escherichia coli* 0111: B4 (L2360) and 2′,7′-dichlorofluorescin diacetate (DCFH-DA, D6883) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Lipid peroxidation assay kit (ab118970), superoxide dismutase (SOD) activity assay kit (ab65354), reduced glutathione (GSH) assay kit (ab235670), mouse interleukin-1 beta (IL-1β, ab197742), IL-6 (ab222503), IL-18 (ab216165), tumor necrosis factor-alpha (TNF-α, ab208348) ELISA kits, lactate dehydrogenase (LDH) activity assay kit (ab102526), myeloperoxidase (MPO) activity assay kit (ab105136), and caspase-1 activity assay kit (ab39412) were all purchased from Abcam (Cambridge, MA, USA). TransAM® NF-κB p65 kit (40097) was purchased from Active Motif (Carlsbad, CA, USA). Pierce BCA protein assay kit (23225) and NE-PER™ nuclear and cytoplasmic extraction reagent (78835) were purchased from ThermoFisher Scientific (Waltham, MA, USA). Compound C (CpC, S840) and GW9662 (S2915) were purchased from Selleck Chemicals (Houston, TX, USA). The agomir (miR40005460-4-5), agomir control (AgNC, miR4N0000003-4-5), antagonim (miR30005460-4-5), and antagonim control (AntagNC, miR3N0000003-4-5) of miR-1224-5p were synthesized by RiboBio Co., Ltd. (Guangzhou, China). The following primary antibodies were purchased from Abcam (Cambridge, MA, USA): anti-nuclear factor E2-related factor 2 (NRF2, ab62352), anti-PPAR-γ (ab209350), while anticapase-1 p10 (sc-56036) was obtained from Santa Cruz Biotechnology (Dallas, Texas, USA). Antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH, 21185), antiphospho AMPKα (P-AMPKα, 2535), and antitotal AMPKα (t-AMPKα, 2603P) were purchased from Cell Signaling Technology (Danvers, MA, USA).

2.2. Animals. Bacterial pneumonia is a common cause of sepsis-related ALI, and LPS is the major virulence factor in the outer membrane of Gram-negative bacteria and is well-accepted to generate sepsis-related organ injury in mice. In the present study, one hundred and two male C57BL/6 mice aged 10-12 weeks old received a single intratracheal injection of LPS (5 mg/kg) and then maintained for 12 h to establish sepsis-related ALI as we previously described, while mice with saline injection were used as the control [19, 26]. To manipulate miR-1224-5p level, mice were intravenously injected with the agomir (30 mg/kg/day), antagonim (80 mg/kg/day), or matched controls for 3 consecutive days before LPS injection [19, 26]. To investigate the role of miR-1224-5p in mortality rate, mice were injected from the trachea with a lethal dose of LPS (25 mg/kg) and monitored every 12 h [19]. To inhibit AMPKα, mice were intraperitoneally with CpC (20 mg/kg) once two days for 3 times before miR-1224-5p antagonim treatment [4]. To inhibit PPAR-γ, mice were pretreated with GW9662 (0.35 mg/kg/day in drinking water) for 10 consecutive days as previously described [27, 28]. The animal protocols were approved by the Animal Experimentation Ethics Committee of Zhongnan Hospital of Wuhan University and were also in accordance with the guidelines of the National Institutes of Health for live animals.

2.3. Functional Determination. Pulmonary function was determined using the Buxco pulmonary function testing system (Connecticut, CT, USA) as previously described [26, 29]. Airway resistance, pulmonary ventilation, lung compliance, tidal volume, and respiratory rate (RR) were recorded from the anesthetized mice.

2.4. Blood Gas Analysis. Arterial blood gas analysis was performed to evaluate pulmonary gas exchange and blood acid-base status [30]. In brief, arterial blood samples were collected from the right common carotid artery using a heparinized PE10 polyethylene catheter, which were then used to determine the arterial blood gas parameters, including partial pressure of oxygen (PaO₂), partial pressure of carbon dioxide (PaCO₂), and sodium bicarbonate (HCO₃⁻) by an automatic blood gas analyzer.

2.5. Lung Wet to Dry Ratio. Lung wet to dry ratio was calculated to evaluate pulmonary edema as we previously
2.6. Bronchoalveolar Lavage Fluid (BALF) Collection and Analysis. The lungs were intratracheally instilled with 1 mL cooled phosphate buffer saline (PBS, pH = 7.4) for 2-3 times to obtain the BALF from a detaining needle inserting to the mouse trachea which was then centrifuged for 10 min at 4°C under a speed of 1600 rpm with the supernatants collected for analysis of cytokines and protein concentrations [31]. Total protein concentrations were measured by the Pierce BCA protein assay kit (ThermoFisher Scientific, Waltham, MA, USA). The lungs were intratracheally instillated with saline (PBS, pH = 7.4): 24 h, and then stimulated with or without LPS (100 ng/mL) or GW9662 (10 μmol/L) for 6 h [4, 19]. To inhibit AMPK α/β24 h, and then stimulated with or without LPS (100 ng/mL) or GW9662 (10 μmol/L) for 24 h, cultured in fresh medium for an additional 24 h, and then stimulated with or without LPS (100 ng/mL) for 6 h [4, 19]. To inhibit AMPK α/β or PPAR-γ, cells were pretreated with CpC (20 μmol/L) or GW9662 (10 μmol/L) for 12 h before miR-1224-5p antagonist treatment [4, 27].

2.7. Cell Culture and Stimulation. Murine peritoneal macrophages were isolated as previously described [32]. In brief, the peritoneal cavity was rinsed with cooled PBS for 2-3 times to obtain the macrophages-enriched solution, which was then centrifuged for 10 min at 4°C. The pelleted macrophages were then resuspended in 0.5 mL PBS, and cell numbers were counted with a hemocytometer and the Wright-Giemsa staining as we recently described [19].

2.8. Western Blot. Total proteins were extracted as previously described [19, 33–35]. Briefly, fresh lungs or macrophages were lysed with RIPA lysis buffer, and then, total protein concentrations were determined using a commercial kit following the manufacturer’s instructions. 20 μg proteins were then separated by SDS-PAGE and transferred onto the PVDF membranes, which were then blocked with 5% BSA for 1.5 h at room temperature and incubated with the indicated primary antibodies overnight at 4°C. After 24 h, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature and visualized with enhanced chemiluminescent reagent. Protein levels were quantified to GAPDH or the total proteins using an Image Lab software (Version 6.0).

2.9. Quantitative Real-Time PCR. Total RNA from lungs or macrophages were prepared using TRIzol reagent and reversely transcribed to cDNA using the Transcriptor First Strand cDNA Synthesis Kit. Quantitative real-time PCR was then performed using SYBR Green Mix, and relative gene expression was quantified to the internal controls using the 2−ΔΔCt method [36–39].

2.10. Determination of Oxidative Stress. ROS productions were determined using a DCFH-DA probe as previously described [19, 40, 41]. In brief, fresh lung homogenates or macrophages lysates were incubated with DCFH-DA (50 μmol/L) for 30 min at 37°C in the dark, and then, fluorescence intensities were examined at an excitation/emission wavelength of 485/535 nm using a BioTek microplate reader. The levels of malondialdehyde (MDA) content, total SOD activity, and GSH content were measured by commercial kits following the manufacturer’s instructions (Abcam; Cambridge, MA, USA).

2.11. Biochemical Analyses. Inflammatory cytokines in BALF or lung homogenates were detected by commercial ELISA kits, and LDH activities in lungs were detected at 450 nm using commercial kit. To evaluate NF-κB activities in vivo and in vitro, nuclear extracts were prepared and incubated with the TransAM® NF-κB p65 kit according to the manufacturer’s instructions (Active Motif, Carlsbad, CA, USA) [42]. In addition, fresh lungs were homogenized with MPO assay buffer, centrifuged to remove the insoluble material, and incubated with the reaction mix and TNB reagent/standard solution, which was then detected at 412 nm. Caspase-1 activities were detected using a commercial kit (Abcam; Cambridge, MA, USA) at an excitation/emission wavelength of 400/505 nm based on the fluorescent substrate YVAD-AFC (AFC: 7-amino-4-trifluoromethyl coumarin).

2.12. Luciferase Reporter Assay. The PPAR-γ 3′-UTR containing a binding site of miR-1224-5p was cloned and inserted into the pGL3 plasmid (Promega; Sunnyvale, CA, USA), which was then transfected to the HEK293T cells for 48 h with or without the miR-1224-5p agomir treatment. Next, cells were lysed, and the luciferase activities were measured by the Dual-Luciferase Reporter Assay System (Promega). Results were calculated as the ratios of Firefly luciferase luminescence to Renilla luciferase luminescence [43–45].

2.13. Statistical Analysis. Comparisons between 2 groups were conducted by an unpaired Student’s t-test, and differences between more than 2 groups were assessed by one-way ANOVA with Turkey post hoc test for post hoc analysis. Statistical analysis was performed using SPSS software (version 23.0). Data represented as the means ± SD. P value less than 0.05 was regarded to be statistically significant.

3. Results

3.1. The miR-1224-5p Antagomir Attenuates LPS-Induced ALI in Mice. We first evaluated the miR-1224-5p levels in lungs from LPS-treated mice. As shown in Figures 1(a) and 1(b), the miR-1224-5p levels in lungs were elevated by LPS injection in time- and dose-dependent manners. Next, ALI mice were treated with the miR-1224-5p antagonist to inhibit pulmonary miR-1224-5p expression (Figure 1(c)). The results showed that the miR-1224-5p antagonist dramatically reduced airway resistance and increased lung ventilation, compliance, and tidal volume (Figures 1(d)–1(g)). In addition, LPS-induced RR suppression was also improved by the miR-1224-5p (Figure 1(h)). Accordingly, results from arterial blood gas analysis revealed that the miR-1224-5p...
Figure 1: Continued.
antagomir significantly increased PaO$_2$ and decreased PaCO$_2$ and HCO$_3^{-}$ in ALI mice (Figures 1(i) and 1(j)). LPS-related ALI is commonly accompanied by pulmonary edema. As expected, we observed an increase of lung wet to dry ratio in LPS-treated mice, which was dramatically reduced by the miR-1224-5p antagomir, indicating an ameliorative pulmonary edema (Figure 1(k)). In accordance with the phenotypic alterations, the miR-1224-5p antagomir also inhibited pulmonary injury in ALI mice, as evidenced by the decreased lung LDH activities and total protein concentrations in BALF (Figures 1(l) and 1(m)). Intriguingly, the miR-1224-5p antagomir-treated mice also showed a decreased mortality rate upon LPS stimulation (Figure 1(n)). Taken together, these findings demonstrate that the miR-1224-5p antagomir attenuates LPS-induced ALI in mice.

3.2. The miR-1224-5p Agomir Aggravates LPS-Induced ALI in Mice. Next, we treated ALI mice with the miR-1224-5p agomir to overexpress miR-1224-5p in lungs, and the efficiency was presented in Figure 2(a). As shown in Figures 2(b)–2(f), LPS injection resulted in an increase of airway resistance and significant decreases of lung ventilation, compliance, tidal volume, and RR, which were further aggravated by the miR-1224-5p agomir. Meanwhile, the miR-1224-5p agomir further compromised LPS-induced impairment of pulmonary gas exchange and blood acid-base status, as evidenced by the decreased PaO$_2$, PaCO$_2$, and HCO$_3^{-}$. (k) Lung wet to dry ratio. (l) LDH activities in lungs. (m) Total protein concentrations in BALF. (n) Mice were intravenously injected with the miR-1224-5p antagomir (80 mg/kg/day) or antagNC for 3 consecutive days and then exposed to a lethal dose of LPS (25 mg/kg), and the survival rate was calculated every 12 h. Data represent the means ± SD (n = 6 per group). *P < 0.05 versus the matched group.

3.3. The miR-1224-5p Antagomir Suppresses Oxidative Stress and Inflammation in ALI Mice. Oxidative stress and inflammation play critical roles in the progression of LPS-induced ALI; therefore, we next evaluated the role of miR-1224-5p in
these pathophysiological processes. As shown in Figure 3(a), LPS injection dramatically increased intrapulmonary ROS generation, which was suppressed by the miR-1224-5p antagomir. Accordingly, MDA levels, a product of lipid peroxidation, were also reduced in the miR-1224-5p antagomir-treated ALI mice (Figure 3(b)). SOD and GSH are required to overcome the increased oxidative stress [32]. We found that the miR-1224-5p antagomir dramatically reduced LPS-induced SOD and GSH depletions (Figures 3(c) and 3(d)). Due to the pivotal role of NRF2 in controlling the transcription of these antioxidant enzymes, we evaluated whether the miR-1224-5p antagomir could affect NRF2 pathway. As shown in Figure 3(e), the miR-1224-5p antagomir effectively enhanced the protein expression of NRF2 in LPS-induced ALI mice. Next, we investigated the effects of the miR-1224-5p antagomir on LPS-induced intrapulmonary inflammatory responses in mice. Our findings demonstrated that the miR-1224-5p antagomir dramatically suppressed the accumulation of total cells, neutrophils, and macrophages in BALF (Figure 4(a)). Meanwhile, the
activities of pulmonary MPO, an index of neutrophil accumulation, were also inhibited by the miR-1224-5p antagomir (Figure 4(b)). In addition, we found that the miR-1224-5p antagomir effectively reduced the levels of IL-6 and TNF-α in lungs and BALF upon LPS treatment (Figures 4(c) and 4(d)). NF-κB functions as a critical molecule to drive the transcription of these inflammatory cytokines [46, 47]. As shown in Figure 4(e), LPS-induced increases of NF-κB activities in lungs were dramatically suppressed by the miR-1224-5p antagomir. Recent findings have identified an indispensable role of NLRP3 in inflammasome in LPS-induced inflammation and ALI; therefore, we next investigated NLRP3 inflammasome activation. Upon ROS stimulation, TXNIP detaches from thioredoxin, binds to NLRP3, and then activates NLRP3 inflammasome to amplify inflammatory response [48, 49]. Consistent with the suppressed oxidative stress, we found that the miR-1224-5p antagomir significantly reduced TXNIP expression. Meanwhile, the protein levels of NLRP3 and caspase-1 p10 were also decreased by the miR-1224-5p antagomir, accompanied by a decreased caspase-1 activities in lungs from ALI mice (Figure 4(f)). Collectively, our results prove that the miR-1224-5p antagomir suppresses oxidative stress and inflammation in ALI mice.

3.4. The miR-1224-5p Agomir Exacerbates Oxidative Stress and Inflammation in ALI Mice. We investigated whether the miR-1224-5p agomir could aggravate LPS-induced oxidative stress and inflammation in lungs. As shown in Figure S1A-B, LPS-induced ROS and MDA formations were further increased in mice treated with the miR-1224-5p agomir. In addition, the miR-1224-5p agomir also suppressed LPS-induced infiltrations of inflammatory cells (Figure S1C-D). Accordingly, expressions of the inflammatory cytokines, including IL-6, TNF-α, IL-1β, and IL-18, in LPS-injured lungs were all increased by the miR-1224-5p agomir. Together, we clarify that the miR-1224-5p agomir exacerbates oxidative stress and inflammation in ALI mice.

3.5. The miR-1224-5p Antagomir Alleviates, while the miR-1224-5p Agomir Aggravates Oxidative Stress and Inflammation in LPS-Stimulated Macrophages. Macrophages are a critical cell type in regulating LPS-induced ALI; therefore, we then investigated the role of miR-1224-5p in LPS-induced oxidative stress and inflammation in macrophages. As shown in Figure 5(a), the miR-1224-5p
|          |         |         |          |         |          |          |          |          |
|----------|---------|---------|----------|---------|----------|----------|----------|----------|
|          |         |         |          |         |          |          |          |          |
| Saline   | LPS     | Saline  | LPS      | Saline  | LPS      | Saline   | LPS      | Saline   |
|          |         |         |          |         |          |          |          |          |
| AntagNC  | Antagom | AntagNC | Antagom  | AntagNC | Antagom  | AntagNC  | Antagom  | AntagNC  |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| 0        | 6       | 0       | 12       | 18      | 0        | 6        | 12       | 18       |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| Saline   | LPS     | Saline  | LPS      | Saline  | LPS      | Saline   | LPS      | Saline   |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| AntagNC  | Antagom | AntagNC | Antagom  | AntagNC | Antagom  | AntagNC  | Antagom  | AntagNC  |
|          |         |         |          |         |          |          |          |          |
| 0        | 5       | 0       | 10       | 15      | 0        | 5        | 10       | 15       |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| Saline   | LPS     | Saline  | LPS      | Saline  | LPS      | Saline   | LPS      | Saline   |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| AntagNC  | Antagom | AntagNC | Antagom  | AntagNC | Antagom  | AntagNC  | Antagom  | AntagNC  |
|          |         |         |          |         |          |          |          |          |
| 0        | 1       | 0       | 2        | 4       | 0        | 1        | 2        | 4        |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| Saline   | LPS     | Saline  | LPS      | Saline  | LPS      | Saline   | LPS      | Saline   |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| AntagNC  | Antagom | AntagNC | Antagom  | AntagNC | Antagom  | AntagNC  | Antagom  | AntagNC  |
|          |         |         |          |         |          |          |          |          |
| 0        | 1       | 0       | 2        | 4       | 0        | 1        | 2        | 4        |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| Saline   | LPS     | Saline  | LPS      | Saline  | LPS      | Saline   | LPS      | Saline   |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| AntagNC  | Antagom | AntagNC | Antagom  | AntagNC | Antagom  | AntagNC  | Antagom  | AntagNC  |
|          |         |         |          |         |          |          |          |          |
| 0        | 500     | 0       | 1000     | 1500    | 0        | 500      | 1000     | 1500     |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| Saline   | LPS     | Saline  | LPS      | Saline  | LPS      | Saline   | LPS      | Saline   |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| AntagNC  | Antagom | AntagNC | Antagom  | AntagNC | Antagom  | AntagNC  | Antagom  | AntagNC  |
|          |         |         |          |         |          |          |          |          |
| 0        | 250     | 0       | 500      | 750     | 0        | 250      | 500      | 750      |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| Saline   | LPS     | Saline  | LPS      | Saline  | LPS      | Saline   | LPS      | Saline   |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| AntagNC  | Antagom | AntagNC | Antagom  | AntagNC | Antagom  | AntagNC  | Antagom  | AntagNC  |
|          |         |         |          |         |          |          |          |          |
| 0        | 10      | 0       | 20       | 40      | 0        | 10       | 20       | 40       |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| Saline   | LPS     | Saline  | LPS      | Saline  | LPS      | Saline   | LPS      | Saline   |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
| AntagNC  | Antagom | AntagNC | Antagom  | AntagNC | Antagom  | AntagNC  | Antagom  | AntagNC  |
|          |         |         |          |         |          |          |          |          |
| 0        | 200     | 0       | 400      | 800     | 0        | 200      | 400      | 800      |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |
|          |         |         |          |         |          |          |          |          |

**Figure 4:** The miR-1224-5p antagomir suppresses inflammation in ALI mice. (a) Mice were intravenously injected with the miR-1224-5p antagomir (80 mg/kg/day) or AntagNC for 3 consecutive days and then exposed to LPS (5 mg/kg) for 12 h. BALF was collected and used to measure the cell numbers. (b) MPO activities in lungs. (c, d) The levels of IL-6 and TNF-α in BALF and murine lungs. (e) NF-κB activities in lungs. (f, g) Protein levels of TXNIP, NLRP3 and caspase-1 p10 in lungs. (h) Relative caspase-1 activities in lungs. (i) The levels of IL-1β and IL-18 in murine lungs. Data represent the means ± SD (n = 6 per group). *P < 0.05 versus the matched group.
Figure 5: Continued.
antagomir significantly reduced miR-1224-5p expressions in LPS-stimulated macrophages. In line with the in vivo data, we demonstrated that LPS-induced ROS and MDA generations were significantly reduced by the miR-1224-5p antagomir (Figures 5(b) and 5(c)). And the suppressions of total SOD activities and GSH contents caused by LPS were also restored by the miR-1224-5p antagomir in macrophages (Figure 5(d)). Meanwhile, the miR-1224-5p antagomir also significantly decreased the levels of NF-κB activities and IL-6 and TNF-α releases (Figures 5(e) and 5(f)). Intriguingly, the activation of NLRP3 inflammasome in LPS-treated macrophages was dramatically suppressed by the miR-1224-5p antagomir, as evidenced by the decreased caspase-1 activities, and TXNIP, NLRP3, and caspase-1 p10 protein levels (Figures 5(g)–5(i)). Meanwhile, the releases of IL-1β and IL-18 from LPS-treated macrophages were also inhibited by the miR-1224-5p antagomir (Figure 5(j)). Conversely, LPS-stimulated macrophages were treated with the miR-1224-5p agomir to overexpress miR-1224-5p expressions in vitro (Figure S2A). As shown in Figure S2B–C, the miR-1224-5p agomir further promoted LPS-induced oxidative stress in macrophages. And the inflammatory response caused by LPS was also amplified by the miR-1224-5p agomir, as evidenced by the increased NF-κB activities, and IL-6, TNF-α, IL-1β, and IL-18 releases (Figure S2D–F). Collectively, the data imply that the miR-1224-5p antagomir alleviates, while the miR-1224-5p agomir aggravates oxidative stress and inflammation in LPS-stimulated macrophages.

3.6. The miR-1224-5p Antagomir Prevents LPS-Induced ALI through Activating AMPKα. Due to the antioxidant and anti-inflammatory effects of AMPKα during LPS-induced ALI, we next investigated whether it was involved in the miR-1224-5p antagomir-mediated pulmoprotection against LPS-induced ALI. As shown in Figures 6(a) and 6(b), AMPKα phosphorylation in lungs was significantly suppressed by LPS injection, which was preserved by the miR-1224-5p antagomir, but further aggravated by the miR-1224-5p agomir. To validate the necessity of AMPKα, mice were pretreated with CpC to inhibit AMPKα as previously described. As shown in Figure 6(c), CpC pretreatment significantly abrogated the miR-1224-5p antagomir-mediated antioxidant effects during LPS-induced ALI. In addition, the miR-1224-5p antagomir-mediated inhibitions on IL-6, TNF-α, IL-1β, and IL-18 were also blocked by CpC (Figures 6(d) and 6(e)). Accordingly, the miR-1224-5p antagomir failed to attenuate LPS-induced pulmonary edema and injury in the presence of CpC, as evidenced by the increased lung wet to dry ratio, LDH activities, and total proteins in BALF (Figures 6(f)–6(h)). The improved pulmonary function and blood gas exchange status by the miR-1224-5p antagomir were also aggravated in CpC-treated mice upon LPS stimulation (Figures 6(i)–6(k)). In line with the in vitro data, the antioxidant and anti-inflammatory effects of the miR-1224-5p antagomir were abolished by CpC in LPS-treated macrophages (Figure S7A–D). These findings show that the miR-1224-5p antagomir prevents LPS-induced ALI through activating AMPKα.

3.7. miR-1224-5p Directly Targets PPAR-γ to Regulate AMPKα Activation. We finally explored the potential targets of miR-1224-5p to regulate AMPKα activation during LPS-induced ALI. Using the online TargetScan Mouse 7.2 software (http://www.targetscan.org/mmu_72/), we observed a putative binding site of miR-1224-5p on the 3′-UTR of PPAR-γ, a nonclassic upstream activator of AMPKα (Figure 7(a)). To validate the direct interaction, a luciferase reporter assay was performed. As shown in Figure 7(b), the miR-1224-5p agomir significantly inhibited the luciferase activity of PPAR-γ 3′-UTR reporter plasmid. In addition, we demonstrated that the miR-1224-5p antagomir increased, while the miR-1224-5p agomir decreased PPAR-γ protein and mRNA levels in lungs from ALI mice (Figures 7(c) and 7(d)). To validate the necessity of PPAR-γ in mediating AMPKα activation by the
Figure 6: Continued.
miR-1224-5p antagomir, LPS-treated mice were injected with GW9662 to inhibit endogenous PPAR-γ. As shown in Figures 7(e) and 7(f), PPAR-γ inhibition dramatically abrogated the miR-1224-5p antagomir-induced activation of AMPKα in ALI mice. Consistently, the antioxidant and anti-inflammatory effects of the miR-1224-5p antagomir were blocked in GW9662-treated mice upon LPS stimulation (Figures 7(g) and 7(h)). Furthermore, the decreased pulmonary edema, injury, and dysfunction in the miR-1224-5p antagomir-treated ALI mice were also blunted by GW9662 (Figures 7(i)–7(l)). In line with the in vivo data, GW9662 also abolished the miR-1224-5p antagomir-mediated antioxidant and anti-inflammatory effects in LPS-treated macrophages (Figure S3A-D). Taken together, our results indicate that miR-1224-5p directly targets PPAR-γ to regulate AMPKα activation.

Figure 6: The miR-1224-5p antagomir prevents LPS-induced ALI through activating AMPKα. (a, b) Mice were intravenously injected with the agomir (30 mg/kg/day), antagomir (80 mg/kg/day), or matched controls for 3 consecutive days and then exposed to LPS (5 mg/kg) for 12 h. Phosphorylated and total AMPKα in lungs were detected. (c) To inhibit AMPKα, mice were intraperitoneally with CpC (20 mg/kg) once two days for 3 times before miR-1224-5p antagomir treatment, and then ROS and MDA levels in lungs were measured. (d, e) The levels of IL-1β, IL-6, IL-18, and TNF-α in murine lungs. (f) Lung wet to dry ratio. (g) LDH activities in lungs. (h) Total protein concentrations in BALF. (i, j) Pulmonary function was detected. (k) Arterial blood gas analysis of PaO₂ and PaCO₂. Data represent the means ± SD (n = 6 per group). *P < 0.05 versus the matched group.
Figure 7: Continued.
4. Discussion

ALI and ARDS are life-threatening lung diseases that closely correlate with multiple organ failure and high mortality rate among patients in the intensive care unit. Infectious etiologies are the common causes of ALI, especially the bacterial pneumonia [1]. LPS is a primary component of the outer membrane in Gram-negative bacteria, and it functions as a
natural ligand of toll-like receptors (TLRs) to activate the downstream proinflammatory signaling cascades [50, 51]. Previous studies have shown that LPS injection from the trachea caused a severe lung injury that characterized by uncontrolled oxidative stress and inflammatory response, phenocopying the sepsis-related ALI in human [4, 19].

Herein, we used LPS injection to establish sepsis-related ALI in mice. Our findings revealed that the miR-1224-5p levels in lungs were dramatically elevated by LPS injection in time- and dose-dependent manners, and that the miR-1224-5p antagonist could alleviate LPS-induced oxidative stress and inflammation in vivo and in vitro, thereby preventing ALI progression. Mechanistically, miR-1224-5p directly bound to and inhibited PPAR-γ expression and subsequently suppressed AMPKα activation-mediated antioxidant and anti-inflammatory effects. In this study, for the first time, we identify an involvement of miR-1224-5p in the progression of LPS-induced oxidative stress, inflammation, and pulmonary dysfunction, and inhibiting miR-1224-5p may help to develop novel therapeutic approaches to attenuate sepsis-related ALI.

AMPKα is well known as an energy sensor in eucaryotic cells and plays critical roles in controlling systemic metabolic homeostasis [52, 53]. However, emerging studies have revealed that AMPKα is also implicated in regulating oxidative stress and inflammation. Hu et al. previously reported that AMPKα activation by matrine could increase uncoupling protein 2 expression and subsequently reduce doxorubicin-induced ROS overproduction in the heart [54]. In addition, AMPKα activation also promoted the expression and nuclear localization of NRF2, which in turn drives the transcription of downstream antioxidant enzymes, such as SOD and GSH [4, 32]. In the present study, we demonstrated that the miR-1224-5p antagonist dramatically suppressed LPS-induced ROS overproduction through activating AMPKα, and that CpC treatment abolished the miR-1224-5p antagonist-mediated antioxidant effects in vivo and in vitro. Inflammation is another feature of sepsis-related ALI. LPS injection directly activates TLR4 and subsequently promotes the phosphorylation and nuclear accumulation of NF-κB, which then drives the transcription of various inflammatory cytokines. The NLRP3 inflammasome functions as a molecular scaffold for the maturation and release of IL-1β and IL-18 [55–57]. LPS-triggered ROS generation promotes the dissociation of TXNIP from thioredoxin, which then interacts with NLRP3 to activate NLRP3 inflammasome. Moreover, NF-κB nuclear accumulation also enhances the transcription of NLRP3 inflammasome components. Activation of NLRP3 inflammasome accelerates the processing and release of multiple inflammatory cytokines that in turn further amplify the inflammatory response cascades. AMPKα activation has been demonstrated to suppress the activation of NF-κB and NLRP3 inflammasome and reduces the levels of IL-1β, IL-6, IL-18, and TNF-α [4, 32]. Accordingly, we herein also showed that CpC treatment blocked the miR-1224-5p antagonist-mediated anti-inflammatory effects in vivo and in vitro. Various classic upstream targets of AMPKα have been identified, such as liver kinase B1, calcium/calmodulin dependent protein kinase 2, and protein kinase A [58]. However, using the online TargetScan Mouse 7.2 software, we identified a potential binding site of miR-1224-5p in PPAR-γ, a nonclassic upstream activator of AMPKα. Previously, Zhang et al. demonstrated that PPAR-γ upregulation by rosmarinic acid significantly increased AMPKα phosphorylation and activity, and that PPAR-γ silence could block rosmarinic acid-mediated AMPKα activation [59]. Consistently, we herein showed that PPAR-γ was essential for AMPKα activation by the miR-1224-5p antagonist. It is worth noting that sepsis-related ALI was generated by LPS injection in this study, a condition unlike the bacterial sepsis-induced ALI to some extent. So the exact role of miR-1224-5p and possible involvement of PPAR-γ/AMPKα axis in sepsis-related ALI should be further validated in a more physiologically relevant condition (e.g., cecal ligation and puncture models).

In conclusion, for the first time, we demonstrated that miR-1224-5p is implicated in the pathogenesis of LPS-induced oxidative stress, inflammation, and pulmonary dysfunction through inactivating PPAR-γ/AMPKα axis, and that targeting miR-1224-5p may help to establish novel therapeutic approaches to treat sepsis-related ALI.

**Data Availability**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Conflicts of Interest**

The authors declare that there are no conflicts of interests.

**Authors’ Contributions**

Bing Liu, Feng Chen, and Ming Xu conceived the hypothesis and designed the study. Bing Liu, Feng Chen, Ni-Tao Cheng, and Zheng Tang carried out the experiments and acquired the data. Bing Liu and Xian-Guo Wang conducted the data analysis. Bing Liu and Ming Xu drafted and revised the manuscript. Bing Liu and Feng Chen contributed equally to this work.

**Acknowledgments**

The study was performed with the employment of Ming Xu.

**Supplementary Materials**

Figure S1: the miR-1224-5p agomir exacerabtes oxidative stress and inflammation in ALI mice. Figure S2: the miR-1224-5p agomir aggravates oxidative stress and inflammation in LPS-stimulated macrophages. Figure S3: miR-1224-5p directly targets PPAR-γ to regulate AMPKα activation in macrophages. (Supplementary Materials)

**References**

[1] E. Fan, D. Brodie, and A. S. Slutsky, “Acute respiratory distress syndrome,” JAMA, vol. 319, no. 7, pp. 698–710, 2018.
[2] Y. Li, Y. Cao, J. Xiao et al., “Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury,” Cell Death and Differentiation, vol. 27, no. 9, pp. 2635–2650, 2020.

[3] T. G. Shah, D. Predescu, and S. Predescu, “Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options,” Clinical and Translational Medicine, vol. 8, no. 1, p. 25, 2019.

[4] W. L. Jiang, K. C. Zhao, W. Yuan et al., “MicroRNA-31-5p exacerbates lipopolysaccharide-induced acute lung injury via inactivating Cab39/AMPKα pathway,” Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 8822361, 2020.

[5] J. Jiang, K. Huang, S. Xu, J. Garcia, C. Wang, and H. Cai, “Targeting NOX4 alleviates sepsis-induced acute lung injury via attenuation of redox-sensitive activation of CaMKII/ERK1/2/MLCK and endothelial cell barrier dysfunction,” Redox Biology, vol. 36, article 101638, 2020.

[6] T. Zhang, J. Liu, S. Shen, Q. Tong, X. Ma, and L. Lin, “SIRT3 promotes lipophagy and chaperon-mediated autophagy to protect hepatocytes against lipotoxicity,” Cell Death and Differentiation, vol. 27, no. 1, pp. 329–344, 2020.

[7] L. Yang, X. Li, A. Jiang et al., “Metformin alleviates led-induced mitochondrial fragmentation via AMPK/Nrf2 activation in SH-SY5Y cells,” Redox Biology, vol. 36, article 101626, 2020.

[8] J. T. Chiou, C. H. Huang, Y. C. Lee et al., “Compound C induces autophagy and apoptosis in parental and hydroquinone-selected malignant leukemia cells through the ROS/p38 MAPK/AMPK/TET2/FoxP3 axis,” Cell Biology and Toxicology, vol. 36, no. 4, pp. 315–331, 2020.

[9] Y. Gui, Q. Lu, M. Gu et al., “Fibroblast mTOR/PPARγ/HGF axis protects against tubular cell death and acute kidney injury,” Cell Death and Differentiation, vol. 26, no. 12, pp. 2774–2789, 2019.

[10] P. Xue, Y. Hou, Z. Zuo et al., “Long isoforms of Nrf1 negatively regulate adipogenesis via suppression of PPARy expression,” Redox Biology, vol. 30, article 101414, 2020.

[11] L. Li, J. Fu, D. Liu et al., “Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: involvement of reduced PPARγ expression,” Redox Biology, vol. 30, article 101412, 2020.

[12] W. Zhang, G. Wang, and S. Zhou, “Protective effects of isorhizigenin on LPS-induced acute lung injury by activating PPARγ,” Inflammation, vol. 41, no. 4, pp. 1290–1296, 2018.

[13] A. T. Reddy, S. P. Lakshmi, A. Banno, and R. C. Reddy, “Role of GPx3 in PPAR-induced protection against COPD-associated oxidative stress,” Free Radical Biology & Medicine, vol. 126, pp. 350–357, 2018.

[14] H. Y. Cho, W. Gladwell, X. Wang et al., “Nrf2-regulated PPAR(gamma) expression is critical to protection against acute lung injury in mice,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 2, pp. 170–182, 2010.

[15] K. Brinkmann, A. P. Ng, C. A. de Graaf et al., “miR17–92 restrains pro-apoptotic BIM to ensure survival of haematopoietic stem and progenitor cells,” Cell Death and Differentiation, vol. 27, no. 5, pp. 1475–1488, 2020.

[16] Y. Chang, H. Jin, H. Li et al., “miRNA-516a promotes bladder cancer metastasis by inhibiting MMP9 protein degradation via the AKT/FOXO3A/SMURF1 axis,” Clinical and Translational Medicine, vol. 10, no. 8, article e263, 2020.

[17] L. L. Lv, Y. Feng, M. Wu et al., “Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury,” Cell Death and Differentiation, vol. 27, no. 1, pp. 210–226, 2020.

[18] Y. D. Jung, S. K. Park, D. Kang et al., “Epigenetic regulation of miR-29a/miR-30c/DNMT3A axis controls SOD2 and mitochondrial oxidative stress in human mesenchymal stem cells,” Redox Biology, vol. 37, article 101716, 2020.

[19] C. Wang, Y. Chen, N. T. Cheng, Z. T. Yang, H. X. Tang, and M. Xu, “MicroRNA-762 modulates lipopolysaccharide-induced acute lung injury via SIRT7,” Immunological Investigations, pp. 1–16, 2021.

[20] H. Lian, P. Xie, N. Yin et al., “Linc00460 promotes osteosarcoma progression via miR-1224-5p/FADS1 axis,” Life Sciences, vol. 233, article 116757, 2019.

[21] Z. Z. Shi, W. J. Wang, Y. X. Chen et al., “The miR-1224-5p/TNS4/EGFR axis inhibits tumour progression in oesophageal squamous cell carcinoma,” Cell Death & Disease, vol. 11, no. 7, pp. 597, 2020.

[22] C. Hu, X. Cheng, Q. MingYu, X. B. Wang, and S. Q. Shen, “The effects of microRNA-1224-5p on hepatocellular carcinoma tumor endothelial cells,” Journal of Cancer Research and Therapeutics, vol. 15, no. 2, pp. 329–335, 2019.

[23] Y. Niu, D. Mo, L. Qin et al., “Lipopolysaccharide-induced miR-1224 negatively regulates tumour necrosis factor-α gene expression by modulating Sp1,” Immunology, vol. 133, no. 1, pp. 8–20, 2011.

[24] W. Cheng, G. P. Liu, D. Kong, W. Huang, Y. Sun, and D. Zhao, “Downregulation of miR-1224 protects against oxidative stress-induced acute liver injury by regulating hepatocyte growth factor,” Journal of Cellular Biochemistry, vol. 120, no. 8, pp. 12369–12375, 2019.

[25] G. Li, J. Jin, S. Liu, K. Ding, and C. Qian, “Inhibition of miR-1224 suppresses hypoxia/reoxygenation-induced oxidative stress and apoptosis in cardiomyocytes through targeting GPX4,” Experimental and Molecular Pathology, vol. 121, article 104645, 2021.

[26] Y. F. Chen, F. Hu, X. G. Wang, Z. Tang, H. X. Tang, and M. Xu, “MicroRNA-23a-5p is involved in the regulation of lipopolysaccharide-induced acute lung injury by targeting HSP20/ASK1,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 9942557, 2021.

[27] W. B. Zhang, Y. F. Zheng, and Y. G. Wu, “Inhibition of miR-128-3p attenuated doxorubicin-triggered acute cardiac injury in mice by the regulation of PPAR-γ,” PPAR Research, vol. 2021, Article ID 7595374, 2021.

[28] L. J. Min, M. Mogi, M. Shadou et al., “ Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice,” Hypertension, vol. 59, no. 5, pp. 1079–1088, 2012.

[29] H. H. Yang, J. X. Duan, S. K. Liu et al., “A COX-2/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation,” Theranostics, vol. 10, no. 11, pp. 4749–47461, 2020.

[30] S. Manzoor, N. Mariappan, I. Zafar et al., “Cutaneous lewisite exposure causes acute lung injury,” Annals of the New York Academy of Sciences, vol. 1479, no. 1, pp. 210–222, 2020.
induced acute lung injury by targeting RPTOR to induce autophagy," *Cell Death & Disease*, vol. 11, no. 8, p. 657, 2020.

[32] X. T. Huang, W. Liu, Y. Zhou et al., "Galectin-1 ameliorates lipopolysaccharide-induced acute lung injury via AMPK-Nrf2 pathway in mice," *Free Radical Biology & Medicine*, vol. 146, pp. 222–233, 2020.

[33] X. Zhang, C. Hu, Y. P. Yuan et al., "Endothelial ERG alleviates cardiac fibrosis via blocking endothelin-1-dependent paracrine mechanism," *Cell Biology and Toxicology*, vol. 37, no. 6, pp. 873–890, 2021.

[34] A. Shahbandi, S. G. Rao, A. Y. Anderson et al., "BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer," *Cell Death and Differentiation*, vol. 27, no. 11, pp. 3097–3116, 2020.

[35] Y. Liu, X. Liu, N. Zhang et al., "Berberine diminishes cancer cell PD-L1 expression and facilitates antimtumor immunity via inhibiting the deubiquitination activity of CSN5," *Acta Pharmacologica Sinica B*, vol. 10, no. 12, pp. 2299–2312, 2020.

[36] C. Hu, X. Zhang, N. Zhang et al., "Osteoclin attenuates inflammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity," *Clinical and Translational Medicine*, vol. 10, no. 3, p. e124, 2020.

[37] D. Coralllo, M. Donadon, M. Pantile et al., "LINC28B increases neural crest cell migration and leads to transformation of trunk sympatheticadrenal precursors," *Cell Death and Differentiation*, vol. 27, no. 4, pp. 1225–1242, 2020.

[38] T. Valente, G. Dentesano, M. Ezquerra et al., "CCAT/ enhancer binding protein δ is a transcriptional repressor of a-synuclein," *Cell Death and Differentiation*, vol. 27, no. 2, pp. 509–524, 2020.

[39] X. Zhang, C. Hu, N. Zhang et al., "Matrine attenuates pathological cardiac fibrosis via RPS5/p38 in mice," *Acta Pharmacologica Sinica*, vol. 42, pp. 573–584, 2021.

[40] X. Zhang, C. Hu, C. Y. Kong et al., "FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT," *Cell Death and Differentiation*, vol. 27, no. 2, pp. 540–555, 2020.

[41] C. Hu, X. Zhang, P. Song et al., "Meterein-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway," *Redox Biology*, vol. 37, article 101747, 2020.

[42] C. Huang, Y. Chen, H. Dai et al., "UBAP2L arginine methylation by PRMT1 modulates stress granule assembly," *Cell Death and Differentiation*, vol. 27, no. 1, pp. 227–241, 2020.

[43] X. Wang, L. Li, K. Zhao et al., "A novel IncRNA _H1TT forms a regulatory loop with HIF-1 α to modulate angiogenesis and tumor growth," *Cell Death and Differentiation*, vol. 27, no. 4, pp. 1431–1446, 2020.

[44] Y. Zhu, L. Gu, X. Lin et al., "LINC00265 promotes colorectal tumorigenesis via ZMIZ2 and USP7-mediated stabilization of β-catenin," *Cell Death and Differentiation*, vol. 27, no. 4, pp. 1316–1327, 2020.

[45] S. Wang, Z. Chen, S. Zhu et al., "PRDX2 protects against oxidative stress induced by _H. pylori_ and promotes resistance to cisplatin in gastric cancer," *Redox Biology*, vol. 28, article 101319, 2020.

[46] E. Sanchez-Lopez, E. M. Ghia, L. Antonucci et al., "NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia," *Cell Death and Differentiation*, vol. 27, no. 7, pp. 2206–2216, 2020.

[47] K. Ziegler, A. T. Kunert, K. Reinmuth-Sezle et al., "Chemical modification of pro-inflammatory proteins by peroxynitrite increases activation of TLR4 and NF-κB: implications for the health effects of air pollution and oxidative stress," *Redox Biology*, vol. 37, article 101581, 2020.

[48] Y. Jia, R. Cui, C. Wang et al., "Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP–NLRP3–GSDMD pathway," *Redox Biology*, vol. 32, article 101534, 2020.

[49] L. Du, J. Wang, Y. Chen et al., "Novel biphenyl diester derivative AB-38b inhibits NLRP3 inflammasome through Nrf2 activation in diabetic nephropathy," *Cell Biology and Toxicology*, vol. 36, no. 3, pp. 243–260, 2020.

[50] J. Liu, S. Du, Q. Kong et al., "HSPA12A attenuates lipopolysaccharide-induced liver injury through inhibiting caspase-11-mediated hepatocyte pyroptosis via PGC-1α-dependent acyloxyacyl hydrolase expression," *Cell Death and Differentiation*, vol. 27, no. 9, pp. 2651–2667, 2020.

[51] H. Chen, Y. Li, J. Wu et al., "RIPK3 collaborates with GSDMD to drive tissue injury in lethal polymicrobial sepsis," *Cell Death and Differentiation*, vol. 27, no. 9, pp. 2568–2585, 2020.

[52] H. Endo, S. Owada, Y. Shida, and M. Tatemiichi, "Metabolic reprogramming sustains cancer cell survival following extracellular matrix detachment," *Redox Biology*, vol. 36, article 101643, 2020.

[53] K. Aquilano, F. Sciarretta, R. Turchi et al., "Low-protein/high-carbohydrate diet induces AMPK-dependent canonical and non-canonical thermogenism in subcutaneous adipose tissue," *Redox Biology*, vol. 36, article 101633, 2020.

[54] C. Hu, X. Zhang, W. Wei et al., "Matrine attenuates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via maintaining AMPK _α_ /UCP2 pathway," *Acta Pharmacologica Sinica B*, vol. 9, no. 4, pp. 690–701, 2019.

[55] P. Wan, W. Su, Y. Zhang et al., "lncRNA H19 initiates microglial pyroptosis and neuronal death in retinal ischemia/reperfusion injury," *Cell Death and Differentiation*, vol. 27, no. 1, pp. 176–191, 2020.

[56] Z. Wang, G. Xu, H. Wang et al., "Icariside II, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity effects of air pollution and oxidative stress," *Cell Death & Disease*, vol. 9, no. 2, pp. 299–313, 2018.

[57] Q. Zhang, Z. G. Ma, Y. P. Yuan et al., "Rosmarinic acid attenuates cardiac fibrosis following long-term pressure overload via AMPKα/Smad3 signaling," *Cell Death & Disease*, vol. 9, no. 2, p. 102, 2018.